Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Arginase is a manganese-dependent metalloenzyme of the urea cycle that catalyzes the hydrolysis of L-arginine to L-ornithine and urea. As a therapeutic agent, arginase is developed in two primary clinical contexts: as an enzyme replacement therapy (such as pegzilarginase) to treat arginase 1 deficiency (hyperargininemia), and as an arginine-depleting antineoplastic therapy (such as PEG-BCT-100) to treat arginine-auxotrophic cancers (including hepatocellular carcinoma, acute myeloid leukemia, and other solid tumors). By depleting systemic L-arginine, therapeutic arginase starves cancer cells that lack the ability to synthesize arginine de novo due to deficient expression of argininosuccinate synthetase (ASS1) or ornithine transcarbamylase (OTC).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on arginase.